Transthyretin Amyloid Cardiomyopathy Clinical Trial
Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301)
The primary objective of this prospective multi-center, open-label study is to evaluate the long-term safety and tolerability of acoramidis in the context of background heart failure therapy. Selected secondary efficacy endpoints and exploratory pharmacokinetic, pharmacodynamic/biomarker endpoints may also be assessed. All participants who complete 30 months of blinded study treatment and the Month 30 assessments of the double-blind treatment period of the Phase 3 ATTRibute-CM trial (AG10-301) may be eligible to participate in this Open Label Extension (OLE) study of acoramidis. The Day 1 visit in Study AG10-304 may be the same day as the Month 30 visit in Study AG10-301. Under these circumstances, the last dose of Investigational Medicinal Product (IMP) in Study AG10-301 will be the night before the day of the Month 30 visit and the first dose of acoramidis in Study AG10-304 will be during the Study AG10-304 Day 1 visit after baseline assessments have been completed.
Currently, tafamidis is approved for the treatment of ATTR-CM in some regions. Participants are not allowed to be treated with tafamidis or any other ATTR-CM-specific approved or investigational treatments, or therapies used off-label or as non-prescription supplements for ATTR-CM at any time during the study. If participants choose treatment with a prohibited medication, they may be asked to discontinue acoramidis and they may be asked to discontinue/withdraw from the study. Under these circumstances, participants will be asked to complete an early termination visit, and a follow-up visit prior to discontinuation/withdrawal.
Participants are not permitted to participate in another interventional clinical trial (with the exception of Study AG10-301) within 30 days prior to dosing and throughout Study AG10-304. Participants who choose to participate in another interventional clinical trial may be asked to withdraw from acoramidis and/or the study. In such cases, participants will be asked to complete an early termination visit and a follow-up visit. Participation in observational and/or registry studies should be discussed with the Medical Monitor.
Completed 30 months of the blinded study treatment in Study AG10-301 and the Study AG10-301 Month 30 visit including assessments and procedures.
Have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
Female participants of childbearing potential who engage in heterosexual intercourse must agree to use a highly effective method of contraception beginning with enrollment and continuing for 30 days after the last dose of acoramidis. Female participants using oral contraceptives must agree to use an additional birth control method. While not considered highly effective, a double-barrier method is acceptable. A male participant who is sexually active with a female of childbearing potential and has not had a vasectomy must agree to use a double-barrier method of birth control.
Acute myocardial infarction, acute coronary syndrome or coronary revascularization within 90 days prior to Day 1 stroke or transient ischemic attack (TIA) within 90 days prior to Day 1.
Has hemodynamic instability, that in the judgment of the Investigator, would pose too great a risk for participation in the study.
Has had a heart and/or liver transplant or is on the heart transplantation list within the year prior to Day 1
Has had implantation of a cardiac mechanical assist device (CMAD) or is scheduled for implantation of a CMAD
Has confirmed diagnosis of light-chain (AL) amyloidosis at any time during Study AG10-301.
Has estimated glomerular filtration rate (eGFR) by modification of diet for renal disease (MDRD) formula < 15 mL/min/1.73 m2 at Month 27 of Study AG10-301 or at any subsequent central lab value prior to Day 1.
Known hypersensitivity to acoramidis, its metabolites, or formulation excipients.
At the end of Study AG10-301 or at Day 1 of Study AG10-304 (or any time during the study), participant is on prohibited medication.
Females who are pregnant or breastfeeding. A negative urine pregnancy test at the Day 1 visit and at each study visit are required for female participants of childbearing potential.
In the judgment of the Investigator or Medical Monitor, has any clinically important ongoing medical condition or laboratory abnormality or condition that might jeopardize the participant's safety, increase their risk from participation, or interfere with the study.
Participation in another interventional clinical trial (with the exception of Study AG10-301) within 30 days prior to dosing. Participation in observational and/or registry studies should be discussed with the Medical Monitor.
Has any condition that in the opinion of the Investigator or Medical Monitor would preclude compliance with the study protocol such as a history of substance abuse, alcoholism, or a psychiatric condition.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 42 Locations for this study
Los Angeles California, 90048, United States
Aurora Colorado, 80045, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60637, United States
Evanston Illinois, 60201, United States
Baltimore Maryland, 21237, United States
Boston Massachusetts, 02118, United States
Rochester Minnesota, 55905, United States
Kansas City Missouri, 64111, United States
Saint Louis Missouri, 63110, United States
Bronx New York, 10461, United States
New York New York, 10010, United States
New York New York, 10032, United States
Rosedale New York, 11422, United States
Durham North Carolina, 27710, United States
Cleveland Ohio, 44195, United States
Portland Oregon, 97239, United States
Philadelphia Pennsylvania, 19104, United States
Pittsburgh Pennsylvania, 15213, United States
Charleston South Carolina, 29425, United States
Dallas Texas, 75390, United States
Salt Lake City Utah, 84132, United States
Richmond Virginia, 23298, United States
Roanoke Virginia, 24014, United States
Seattle Washington, 98195, United States
Spokane Washington, 99204, United States
Adelaide , , Australia
Box Hill , , Australia
Hobart , , Australia
Murdoch , , Australia
Sydney , 2010, Australia
Woolloongabba , , Australia
Genk Limburg, , Belgium
Brugge West Vlaanderen, , Belgium
RibeirÃ£o Preto Sao Paulo, 14026, Brazil
SÃ£o Paulo Sao Paulo, , Brazil
Porto Alegre , , Brazil
Vancouver British Columbia, V5Z 1, Canada
Winnipeg Manitoba, R2H 2, Canada
Halifax Nova Scotia, B3H 3, Canada
Toronto Ontario, M4P I, Canada
MontrÃ©al Quebec, H2X 0, Canada
MontrÃ©al Quebec, H4J 1, Canada
Rimouski Quebec, G5L 5, Canada
MontrÃ©al , , Canada
Praha Prague, , Czechia
Praha Prague, , Czechia
Brno South Moravian, , Czechia
Aarhus Dinamarca, 8200, Denmark
Athens Attica, , Greece
Dublin , , Ireland
Jerusalem , , Israel
Tel Hashomer , , Israel
Arezzo , , Italy
Firenze , , Italy
Pavia , 27100, Italy
Pisa , , Italy
Seongnam-si Gyeonggi-Do, 13620, Korea, Republic of
Seoul Gyeonggi-Do, 13620, Korea, Republic of
Groningen , , Netherlands
Utrecht , , Netherlands
Papatoetoe Auckland, 2025, New Zealand
Hamilton Waikato, 3240, New Zealand
Lisboa , , Portugal
Santiago De Compostela La CoruÃ±a, , Spain
Majadahonda Madrid, , Spain
Pamplona Navarra, , Spain
Madrid , , Spain
Palma De Mallorca , , Spain
Valencia , , Spain
London England, NW3 2, United Kingdom
London , SE1 1, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.